Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €79.05 EUR
Change Today -0.168 / -0.21%
Volume 935.0
S7E On Other Exchanges
S7E is not on other exchanges.
As of 1:36 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc (S7E) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/15 - €79.62
52 Week Low
10/15/14 - €40.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SHIRE PLC (S7E)

shire plc (S7E) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc (S7E) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc (S7E) Key Developments

Shire and Foundation Fighting Blindness Announce New Research Agreement

Shire plc and the Foundation Fighting Blindness announced a new agreement focused on furthering research for a novel treatment for autosomal dominant retinitis pigmentosa (adRP), a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There are no currently approved treatment options for adRP. As part of the agreement, the Foundation Fighting Blindness and its research partners will provide Shire with expert knowledge and scientific background regarding adRP, as well as pertinent clinical information that could be useful in the development of a drug to treat adRP. Backed by its scientific advisory board, the Foundation Fighting Blindness will also provide counsel as requested on the pre-clinical and/or clinical development of Shire compounds in development for the treatment of adRP. Shire is compensating the Foundation Fighting Blindness for its considerable expertise in early-stage drug discovery and development, as well as making available it significant expertise and experience with the submission of investigational new drug applications.

Shire plc Appoints Jeff Poulton as Chief Financial Officer, Member of the Executive Committee and to Board of Directors

Shire plc announced the appointment of Jeff Poulton as Chief Financial Officer (CFO) and member of the Executive Committee. Jeff will additionally join the company's Board of Directors. Both appointments are effective immediately. Jeff has served as Interim CFO since December 2014, while overseeing Investor Relations. As CFO, he will remain based in Lexington. An experienced pharmaceuticals and biotechnology executive, Jeff has experience across financial, commercial and strategic leadership roles. He joined the company in 2003. Jeff's experience at the company includes leading the Global Rare Diseases business unit, and overseeing the integration of Viropharma's rare diseases products into the company's portfolio. Previously, Jeff served in diverse corporate finance and business development roles for Cinergy Corp. and PPG Industries.

Shire plc Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for the Year 2015

Shire plc reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the period, the company reported total revenues of USD 1,488.4 million against USD 1,346.8 million for the same period in the last year. Operating income from continuing operations was USD 474.6 million against USD 306.9 million for the same period in the last year. Income from continuing operations before income taxes and equity in losses of equity method investees was USD 471.3 million against USD 304.3 million for the same period in the last year. Income from continuing operations, net of tax was USD 412.9 million or 69.7 cents per diluted share against USD 253.1 million or 43.0 cents per diluted share a year ago. Net income was USD 410.4 million or 69.3 cents per diluted share against USD 230.4 million or 39.1 cents per diluted share for the same period in the last year. Earnings per ADS - diluted were 207.9 cents against 117.3 cents for the same period in the last year. Net cash provided by operating activities was USD 561.6 million against USD 246.1 million for the same period in the last year. Purchases of non-current investments and PP&E were USD 22.3 million against USD 15.6 million for the same period in the last year. Non-GAAP operating income from continuing operations was USD 682.6 million against USD 590.8 million for the same period in the last year. Non GAAP cash generation was USD 515.8 million against USD 331 million a year ago. Capital expenditure was USD 19.8 million against USD 15.3 million a year ago. Non GAAP EBITDA was USD 714.9 million against USD 627.6 million for the same period in the last year. Non GAAP diluted earnings per American Depository Share (ADS) increased 20% to USD 2.84 against USD 2.36 a year ago, primarily due to the higher Non GAAP operating income and a lower effective tax rate on Non GAAP income. On a US GAAP basis diluted earnings per ADS increased 77% primarily due to higher US GAAP operating income and a lower effective tax rate on US GAAP income. Cash generation, a Non GAAP measure, was 56% higher compared to last year same period, due to strong cash receipts from higher sales and the benefit in First Quarter 2015 from the timing of rebate payments. Net debt (a Non GAAP measure) at March 31, 2015 was USD 2,588 million. Sales for the quarter were 9% increase over the first quarter of 2014, up 13% on a constant exchange rate basis. This was led by significant growth across several products in its portfolio. Based on current exchange rates, the company anticipates low-to-mid single digit product sales growth in 2015, as the company expects growth to be held back 3% to 4% points by foreign exchange headwinds which particularly impact ELAPRASE, REPLAGAL and VPRIV sales. Non GAAP gross margin is expected to be in line with 2014 of 85.8%. The company expects Non GAAP net interest and other expense to be in line with 2014 levels. For the year 2015, the company expects its effective tax rate on Non GAAP income to be in the range of 15%-17%, before reverting to the 17%-19% range in 2016 and beyond. Taken together, the company reiterates its guidance for the full year 2015, and remains confident in delivering Non GAAP diluted earnings per ADS growth in the mid-single digits in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
S7E:GR €79.05 EUR -0.168

S7E Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$93.81 AUD +1.21
Eisai Co Ltd ¥7,967 JPY +32.00
Hospira Inc $88.44 USD +0.04
Mylan NV $72.68 USD +0.64
UCB SA €64.64 EUR +1.18
View Industry Companies

Industry Analysis


Industry Average

Valuation S7E Industry Range
Price/Earnings 14.9x
Price/Sales 8.3x
Price/Book 5.7x
Price/Cash Flow 14.3x
TEV/Sales 8.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at